Board Certification

  • Urology

Areas of Expertise

  • Endourology
  • Laparoscopic and Minimally Invasive Surgery
  • Prostate Cancer
  • Stone Disease
  • Stress and Urge Incontinence



William Beaumont Hospital
Urology Residency
Royal Oak, MI
1997 – 2001

William Beaumont Hospital
General Surgery Residency (PGY I-II)
Royal Oak, MI
1995 – 1997

Medical School

University of Michigan Medical School
Doctor of Medicine
Ann Arbor, MI

Undergraduate School

Andrews University
Bachelor of Science in Biochemistry
Minor in Business Administration
Summa Cum Laude
Berrien Springs, MI

Hospitals Affiliated With

Inova Fair Oaks Hospital
Inova Fairfax Hospital
Prince William Medical Center

Professional Associations

American Urological Association (AUA)
1997 – Present

Mid-Atlantic AUA
2001 – Present

Prince William Medical Society
2004 – Present

Academic Appointments

Malcolm Grow Medical Center, Andrews AFB, MD
Assistant Chief of Urology
2002 – 2004

Uniformed Services University of the Health Sciences (USUHS)
Assistant Professor of Surgery
2002 – 2004

Center for Prostate Disease Research Database, Malcolm Grow Medical Center
Principal Investigator
2002 – 2004

Military Service

Active Duty, Major, USAF, 89th MDG/SGCXU, Andrews AFB, MD
2001 – 2004

Inactive Reserves, United States Air Force
1991 – 2001


Dr. Chung graduated from University of Michigan medical school in 1995 and performed his urologic residency at William Beaumont Hospital in Detroit, Michigan. He was stationed at Andrews AFB for three years with privileges at Walter Reed Army Medical Center and National Naval Medical Center as well. During that time, he was actively involved in the Department of Defense prostate cancer database ( He came to Prince William Hospital in 2004 and has been an active member of the Cancer Committee since 2004. He has strong interests in prostate cancer, endourology, laparoscopic and minimally invasive surgery, stress and urge incontinence and stone disease.

He is board certified by the American Board of Urology. He has been published in multiple medical journals including the Journal of Urology, Urology, Cancer, Journal of Clinical Oncology and Surgery.


Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O’Reilly K, Hernandez J, Chung A, Soderdahl D. J Urol 2004 March;171(3):1141-1147.

Watchful Waiting and Factors Predictive of Secondary Treatment of Localized Prostate Cancer. Wu, H, Sun L, Moul JW, McLeod, DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D. J Urol 2004 March;171(3):1111-1116.

Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG. J Clin Oncol. 2004 Feb 1;22(3):439-45.

Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database.
Moul JW, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T. Urol Oncol. 2003 Nov-Dec;21(6):447-55.

Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackmaan S, Moul JW. J Clin Oncol. 2003 Nov 1;21(21):4001-8.

Pretreatment total testosterone level predicts pathologic stage in radical prostatectomy patients with localized prostate cancer. Massengill JC, Sun, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T. J Urol 2003 May; 169(5):1670-1675.

Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Moul JW; Wu H; Sun L; McLeod DG; Amling C; Lance R; Kusuda L; Donahue T; Foley J; Chung A; Sexton W; Soderdahl D; Rich NM Surgery 2002 Aug;132(2):213-9

Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system. a radiation oncology report of the Department of Defense Center for Prostate Disease Research. Johnstone PA; Riffenburgh RH; Moul JW; Sun L; Wu H; McLeod DG; Kane CJ; Martin DD; Kusuda L; Lance R; Douglas R; Donahue T; Beat MG; Foley J; Chung A; Soderdahl D; Do J; Amling CL. Int J Radiat Oncol Biol Phys 2003 Mar 15;55(4):964-9

“Epidemiology of the Dysfunctional Urinary Sphincter”, by Chung AK, Peters KM, and Diokno AC. The Urinary Sphincter, Marcel Dekker Inc., New York 2001.

“Glanuloplasty and in situ tubularization of the urethral plate: long-term followup” Kass EJ, Chung AK. J Urol 2000 Sep;164(3 Pt 2):991-3

“A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution” Martinez AA, Gonzalez JA, Chung AK, Kestin LL, Balasubramaniam M, Diokno AC, Ziaja EL, Brabbins DS, Vicini FA. Cancer 2000 Jan 15;88(2):425-32

“Neurofibromatosis with involvement of the prostate gland”, by Chung AK, Michels V, Poland GA, King BF, Wojno KJ, Oesterling JE. Urology 47(3):448-51, 1996 March

“Compliance and complications of clean intermittent catheterization in the spinal cord injured patient” by Chai T, Chung AK, Belville WD, Faerber GJ. Paraplegia 33(3): 161-3, 1995 March

Prince William Hospital Annual Cancer Report – 2005, 2009, 2013